The present invention relates generally to lipid membranes. More particularly, the present invention relates to methods of fabricating lipid bilayer membranes on solid supports.
Supported lipid bilayers formed by the fusion of small unilamellar vesicles onto silicon oxide or organic film-modified surfaces enable the biofunctionalization of inorganic solids, such as semiconductors, gold-covered surfaces, and optoelectronic and lab-on-a-chip devices. They have proven valuable in the study of the characteristics and behavior of membrane-bound proteins, membrane-mediated cellular processes, protein-lipid interactions, and biological signal transduction. Because of the complexity of biomembranes, there is a clear need to develop model membrane systems, where one or a few membrane components can be isolated and studied. In addition, a wide range of available surface-sensitive techniques can be used to study natural biological systems effectively by supporting model membranes on a solid surface. Applications of supported membranes on solid surfaces potentially include biosensors, programmed drug delivery, the acceleration and improvement of medical implant acceptance, and the production of catalytic interfaces.
In order to mimic natural biological systems, researchers have employed vesicle fusion methods to form supported bilayers on substrates such as glass, mica, self-assembled monolayers, and quartz. However, it has proven problematic to create planar lipid bilayers on preferred solid substrates, such as gold and TiO2. For example, scientists have attempted to modify gold surfaces using self-assembled monolayers (SAMs), which may require special synthesis, but the structure of the SAMs that are formed may not be well-defined. Accordingly, there is a need in the art to develop new methods of forming supported bilayers on preferred substrates.
The present invention provides a method of producing a planar lipid bilayer on a solid support. With this method, a solution of lipid vesicles is first deposited on the solid support. Next, the lipid vesicles are destabilized by adding an amphipathic peptide solution to the lipid vesicle solution. This destabilization leads to production of a planar lipid bilayer on the solid support. Preferably, the amphipathic peptide is an alpha-helical peptide. More preferably, the alpha-helical peptide is a polypeptide having the entirety or a portion of the sequence SEQ ID NO: 1.
The present invention also provides a supported planar lipid bilayer, where the planar lipid bilayer is made of naturally occurring lipids and the solid support is made of unmodified gold or titanium oxide. Preferably, the supported planar lipid bilayer is continuous. The planar lipid bilayer may be made of any naturally occurring lipid or mixture of lipids, including but not limited to phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, cardiolipin, cholesterol, and sphingomyelin.
The present invention together with its objectives and advantages will be understood by reading the following description in conjunction with the drawings, in which:
The amphipathic peptide is preferably an alpha-helical peptide. More preferably, the amphipathic peptide is the AH peptide of the HCV nonstructural protein NS5A. This peptide is conserved across HCV isolates and has the sequence SEQ ID NO: 1. Either the entire peptide, amino acids 1-16 of the peptide (AH_S1), or amino acids 17-31 of the peptide (AH_S2) may be used to destabilize the lipid vesicles. Alternatively, the peptide may not have the exact sequence of SEQ ID NO: 1, as long as its amphipathic alpha-helical nature is preserved. For example, as shown by circular dichroism, the peptide may have a sequence that is at least about 80% identical to SEQ ID NO: 1, while still maintaining alpha-helicity. Preferably, the concentration of amphipathic peptide in the peptide solution is between about 0.05 μg/ml to 0.5 μg/ml. The amphipathic peptide may be contained in a variety of solvents, including biological buffers (such as Tris buffer, PBS buffer, and HEPES Buffer) and dimethylsulfoxide (DMSO).
Lipid vesicles suitable for the present invention are preferably between about 25 nm and about 80 nm in diameter. The vesicles may be prepared using any method known in the art, including but not limited to extrusion methods. The vesicles are preferably at a concentration of about 0.05 mg/ml to about 5 mg/ml in a biological buffer, such as Tris, PBS, and HEPES buffer, with NaCl concentration of about 100 mM to about 250 mM. Any lipid or mixture of lipids may be used to form the lipid vesicles, including but not limited to phospholipids. Preferred lipids are phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, cardiolipin, cholesterol, and sphingomyelin.
Any solid support may be used according to the present invention. Example materials include, but are not limited to silicon-containing materials, gold, platinum, and titanium oxide.
The present invention also provides supported planar lipid bilayers produced using the method of the present invention. Preferably, the lipid bilayer is composed of naturally occurring lipids and the solid support is made of unmodified gold or titanium oxide. Any naturally occurring lipid may be used for the bilayer, such as phospholipids. Preferred lipids are phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, cardiolipin, cholesterol, and sphingomyelin. Preferably, planar lipid bilayers according to the present invention are continuous, i.e. there are no gaps in the layer.
Formation of a Planar Lipid Bilayer on a Sold Substrate
Bilayer formation from intact vesicles was characterized using a quartz crystal microbalance-dissipation (QCM-D) instrument. To interpret the QCM-D results, a linear relationship between Δf and adsorbed mass (Δm) derived from the classical Sauerbrey equation was employed:
where C is the mass-sensitivity constant with value 17.7 ngcm−2Hz−1 for the QCM-D crystal at 5 MHz, and n is the overtone number (n=1 for the fundamental and 3, 5, 7 for the overtones). The QCM-D has been used in numerous studies of the vesicle fusion process, where the dissipation is used to distinguish between rigid lipid bilayers and monolayers and soft deformable vesicles (see, e.g., Keller and Kasemo, “Surface specific kinetics of lipid vesicle adsorption measured with a quartz crystal microbalance”, Biophys J. 1998 Sep; 75(3):1397-1402).
In order to investigate the ability of AH peptides to rupture vesicles, we tested unilamellar vesicles of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) extruded through 30 nm polycarbonate etch-tracked (PEC) membranes on a gold surface in the absence of the AH peptide, then applied the peptide to form a bilayer. When vesicles adsorb, a large amount of trapped water exists within the intact vesicles as well as between vesicles adsorbed on the surface. This trapped water is able to dissipate a large amount of energy, unlike the water that rests on top of a bilayer. This change in energy dissipation can in turn be used to track the transition between an intact vesicle and a bilayer.
In
In
Formation of a Planar Lipid Bilayer on a TiO2 Substrate
In order to investigate the ability of AH peptides to rupture vesicles on a TiO2 surface, we tested unilamellar vesicles of POPC extruded through 30 nm PEC membranes on a TiO2 surface in the absence of the AH peptide, then applied the peptide to form a bilayer (
In
AFM Analysis of Lipid Bilayer Formation According to the Present Invention
AFM was utilized in order to confirm and directly display rupture of vesicles and bilayer formation by the destabilizing agent the AH peptide.
In
The AFM images in
As one of ordinary skill in the art will appreciate, various changes, substitutions, and alterations could be made or otherwise implemented without departing from the principles of the present invention. Accordingly, the scope of the invention should be determined by the following claims and their legal equivalents.
This application is a national stage filing under 35 U.S.C. §371 of International Patent Application Ser. No. PCT/US2006/012085, which was filed on Mar. 29, 2006 and which was published in English under PCT Article 21(2) as WO 2006/110350 on Oct. 19, 2006, which International Patent Application claims benefit of priority of U.S. Provisional Patent Application Ser. No. 60/666,647, filed Mar. 29, 2005, which applications are incorporated herein by reference in their entirety.
This invention was made with Government support under contracts NAG-8-1843 awarded by the NASA Marshall Space Flight Center and 0213618 awarded by the National Science Foundation. The Government has certain rights in this invention.
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/US2006/012085 | 3/29/2006 | WO | 00 | 4/23/2009 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2006/110350 | 10/19/2006 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
5364851 | Joran | Nov 1994 | A |
5502022 | Schwarz et al. | Mar 1996 | A |
5521702 | Salamon et al. | May 1996 | A |
5846814 | Galla et al. | Dec 1998 | A |
6306598 | Charych et al. | Oct 2001 | B1 |
6306958 | Dirschl et al. | Oct 2001 | B1 |
6344436 | Smith et al. | Feb 2002 | B1 |
6756078 | Bookbinder et al. | Jun 2004 | B2 |
20050201973 | Virtanen et al. | Sep 2005 | A1 |
20050250158 | Parikh et al. | Nov 2005 | A1 |
20060068503 | Cuppoletti | Mar 2006 | A1 |
20060068504 | Kogi | Mar 2006 | A1 |
20070224637 | McAuliffe et al. | Sep 2007 | A1 |
20070224639 | Matsushita et al. | Sep 2007 | A1 |
20080033190 | Lee et al. | Feb 2008 | A1 |
20080125367 | Glenn et al. | May 2008 | A1 |
20110091864 | Karlsson et al. | Apr 2011 | A1 |
Number | Date | Country | |
---|---|---|---|
20090263670 A1 | Oct 2009 | US |
Number | Date | Country | |
---|---|---|---|
60666647 | Mar 2005 | US |